



Adams Business Associates.

Tel: 44-(0)1494-465244

Email: aba@a-b-a.co.uk

Products & Services in Life Science Research Markets – Asia Volume 2 – South East Asia & Pacific Rim 4th Edition - ABA 355.4: September 2020

1. Introduction & Purpose	1
2. Country Demographic Profiles for the Pacific Rim Countries.	4
2.1. Regional Data & Overview	4
2.2. Country Data Overview – Group 1	6
Group 2 Country	8
Group 3 Country	10
General	12
3. Technology & Applications in Pacific Rim	14
3.1 Product Overview	14
3.2. Red Biotechnology	16
3.3. Green & Blue Biotechnology	22
3.4. White Biotechnology	25
3.5. Biotechnology Products	26
4. Group 1 Country Business & Life Sciences Environment Australia, (South) Korea, Singapore, Taiwan & Hong Kong	30
4.1. General Strategic Events 2017-2020	30
4.2. Australia	33
4.2.1. Business and Science & Technology Environment	33
4.2.2. Life Science & Biotechnology Environment	38



4.3. South Korea	55
4.3.1. Business Environment	55
4.3.2. Life Science & Technology Environment	57
4.3.3. Biotechnology Environment	64
4.4. Singapore	86
4.4.1. Business Environment	86
4.4.2. Life Science Business Environment	95
4.4.3. Biotechnology Business Environment	103
4.5. Taiwan	107
4.5.1. Business and Science & Technology Environment	107
4.5.2. Life Science & Biotechnology Environment	109
4.5.3. Business & Commercial Developments in 2016/2017 for Taiwan	114
4.6. Hong Kong	131
4.6.1. Business and Science & Technology Environment	131
4.6.2. Life Sciences Environment	136
4.6.3. Biotechnology Environment	142
4.7. Group 1 Market Quantification: – Australia, Korea, Singapore, Hong Kong, Taiwan	154
4.7.1. General Market Overview for Group 1 Countries	154
4.7.2. Market Segmentation & Funding in Group 1 Countries	154
4.7.3. Product Group & Product Class Markets in Group 1 Countries, 2019	159
Australia	161
South Korea	162
Singapore	163
Taiwan	164
Hong Kong	165
4.7.4. Group 1 Listed Biotechnology Companies, 2019	167



5. Group 2 Country Business & Life Sciences Environment: Malaysia, New Zealand, Thailand & Vietnam	168
5.1. Malaysia	168
5.1.1. Business Environment, Malaysia	168
5.1.2. Life Science and Science & Technology Environment	169
5.1.3. Biotechnology Environment	176
5.2 New Zealand	194
5.2.1. Business Environment, New Zealand	194
5.2.2. Life Science Business Environment	197
5.2.3. Biotechnology Business Environment, New Zealand	205
5.3 Thailand	214
5.3.1. Business Environment, Thailand	214
5.3.2. Science & Technology Environment	217
5.3.3. Biotechnology Business Environment, Thailand	221
5.4 Vietnam	237
5.4.1. Business Environment, Vietnam	237
5.4.2. Science & Technology Environment, Vietnam	239
5.4.3. Biotechnology Business Environment, Vietnam	244
6. Group 3 Country Business & Life Sciences Environment: Indonesia, Philippines, Myanmar & Brunei	263
6.1. Indonesia	263
6.1.1. Business Environment – Indonesia	263
6.1.2. Science & Technology Business Environment, Indonesia	265
6.1.3 Life Science & Biotechnology Business Environment in Indonesia	269



Adams Business Associates.

Tel: 44-(0)1494-465244

Email: aba@a-b-a.co.uk

6.2. Philippines	277
6.2.1. Business Environment Philippines	277
6.2.2 Life Science Business Environment Philippines	279
6.2.3 Biotechnology Business Environment, Philippines	282
6.3 Myanmar (Burma)	292
6.4. Brunei Darussalam	300
6.5. Group 3 Market Quantification	306
6.6. Emerging Countries - Nepal, Cambodia, Laos & Mongolia	314
6.6.1. Nepal	315
6.6.2. Cambodia	317
6.6.3. Laos	318
6.6.4. Mongolia	322
6.6.5. Conclusion	324
7. Asia Pacific & Australasia Life Science Research Business Market Comparisons, 2019 & 2026	325
7.1. Introduction	325
7.2 Infrastructure Comparisons	327
7.3. Applications Comparisons	329
7.4. Product Group and Product Class Comparisons	330
7.5. Conclusion Asia Pacific Life Sciences & Biotechnology Research Markets, 2019 & 2026	333
7.6. Life Science Reagent Company Suppliers	334
Appendix 1 - Currency Exchange Rates, December 2017 & December 2019 & GDP Growth	338
Appendix 2 – Product Descriptions	339



Figures

1. Introduction & Purpose _____ 1

Figure 355.4.1 New reports for ABA Global Library for Life Science Research _____ 1

Figure 355.4.2 ABA Global Library for Life Science Research Reports – 2020 Status _____ 2

2. Country Demographic Profiles for the Pacific Rim Countries. _____ 4

Figure 355.4.3 Asian & Pacific Rim Pharmaceutical Markets, 2019 _____ 5

Figure 355.4.4 Asia Pacific Group 1 Countries Profile & Comparison – in \$US, 2019 _____ 5

Figure 355.4.5 Asia Pacific Group 1 Countries Economic Factors, 2019 _____ 7

Figure 355.4.6 Asia Pacific Group 2 Countries Profile & Comparison – in \$ US 2019 _____ 8

Figure 355.4.7 Asia Pacific Group 2 Countries Economic Factors, 2019 _____ 9

Figure 355.4.8 Asia Pacific Group 3 Countries Profile & Comparison – in \$ US, 2019 _____ 10

Figure 355.4.9 Asia Pacific Group 3 Countries Economic Factors, 2019 _____ 11

Figure 355.4.10 Medical Device 5-Year Market Growth Projections,
2013, 2015, 2016 & 2019 _____ 12

3. Technologies & Applications _____ 14

Figure 355.4.11 Life Science Research Products in South East Asia & Australasia, 2019 _____ 18

Figure 355.4.12 Life Science Applications & Technologies S.E. East Asia
& Australasia, 2019 _____ 19

Figure 355.4.13 Healthcare Services in Pacific Rim Countries, 2019 _____ 20

Figure 355.4.14 Life Science Green Biotechnology Research Focus Areas in Pacific Rim _____ 22

Figure 355.4.15 BioFuel Production in Pacific Rim, 2019 _____ 29

4. Group 1 Country Business & Life Sciences Environment: Australia, (South) Korea, Singapore, Taiwan & Hong Kong _____ 30

Figure 355.4.16 – Strategic Impact Events – Australia 2017-2020 _____ 30

Figure 355.4.16 (*continued*) – South Korea, Singapore & Taiwan, 2017-2020 _____ 31

Figure 355.4.16 (*continued*) – Hong Kong, 2017-2020 _____ 32

Figure 355.4.17 Science & Technology Policy Structure for Australia _____ 36

Figure 355.4.18 Government Life Science Research Institutes in Australia, 2019 _____ 39



Figure 355.4.19 Australian State Life Science Research Status, 2019 (3 Tables)	40 - 42
Figure 355.4.20 Application Areas for Australian Life Science Industry, 2019/20	43
Figure 355.4.21 Spread of Australian Life Science Industry by State, 2019/20	44
Figure 355.4.22 Australian Life Science Features by State, 2019/20	45
Figure 355.4.23 Publicly Listed Australian Life Science Companies	46
Figure 355.4.24 Australian Company Developments in Recent Years	48
Figure 355.4.25 Historical Australia & New Zealand Partnerships with Asian Links	52
Figure 355.4.26 Australia Business & Market Developments, 2016/17	53
Figure 355.4.27 Australia Panel, 2017/20	54
Figure 355.4.28 Science & Technology Organisation in Korea, 2019	59
Figure 355.4.29 Biotechnology Development in Korea, 1983-2008	65
Figure 355.4.30 Major Biotechnology Focus Areas for Korea, BioVision 2016 Programme	65
Figure 355.4.31 Business & Commercial Development in Korea, 2016 – 2019	68
Figure 355.4.32 Domestic Market for Korean Biotechnology, 2019	69
Figure 355.4.33 Korean Biotechnology Companies, 2019 Korea Biotec Database	70
Figure 355.4.34 Sector Focus for Korean Biotechnology Companies, 2019	71
Figure 355.4.35 Life Science Product Sectors, Products & End Users in Korea, 2019	72
Figure 355.4.36 Biotechnology Support & Investments by Major Corporations in Korea	73
Figure 355.4.37 Bio Support Centre Projects in Korea	76
Figure 355.4.38 Biotechnology Clusters & Focus Areas in Korea, 2019	77
Figure 355.4.39 Life Science Research in Universities & Research Institutes in Korea	78
Figure 355.4.40 Advances in Major South Korean Research Institutes, 2019	79
Figure 355.4.41 Korean Derived Healthcare Products	80
Figure 355.4.42 Korean Biotechnology Scenario, 2018/20	81
Figure 355.4.43 Sample of Biotechnology Companies in Korea	83/84
Figure 355.4.44 Evolving Korean Pharma & Biotech Clusters	85
Figure 355.4.45 Science & Technology Organisation in Singapore, 2016 to 2019	89
Figure 355.4.46 International BioPharma./Biotech Activities in Singapore	92
Figure 355.4.47 Singapore Business BioPharmaceutical /Biotechnology Activities	93
Figure 355.4.48 Key Biotechnology Environment Areas for Singapore, 2015/2016	95
Figure 355.4.49 Government Funding for Biotech & Related Areas in Singapore, 2019	96
Figure 355.4.50 Singapore Biotechnology Scenario, 2018/19	97



Figure 355.4.51 Life Science & Biotechnology Research in Universities in Singapore	100
Figure 355.4.52 Key Life Science Research Institutes & Research Areas in Singapore	101
Figure 355.4.53 Sample Indigenous Biotechnology Companies in Singapore	102
Figure 355.4.54 Historical Examples of Singapore Based Biotechnology Companies	103
Figure 355.4.55 Sector Focus for Singapore Biotechnology Companies, 2019	105
Figure 355.4.56 Singapore Country Panel, 2019/20	106
Figure 355.4.57 Science & Technology Organisation in Taiwan, 2018/2019	110
Figure 355.4.58 Government Framework for Biotechnology Development in Taiwan, 2014/19	111
Figure 355.4.59 Science & Technology & Biotechnology Development in Taiwan	112
Figure 355.4.60 Taiwan Science Parks, 2019	113
Figure 355.4.61 Taiwan Science Parks & Biotechnology Clusters, 2019	114
Figure 355.4.62 Biological Sectors in Taiwan, 2019	116
Figure 355.4.63 Emerging Biotechnology Markets in Taiwan, 2019	117
Figure 355.4.64 Biotechnology Industry Focus Areas & Activities in Taiwan, 2019	118
Figure 355.4.65 Integrated R&D Structure for Biotechnology Research in Taiwan, 2019	119
Figure 355.4.66 Life Science Research in Universities in Taiwan, 2019/20	120
Figure 355.4.67 Taiwan Biotechnology Industry Applications, 2019/20	121
Figure 355.4.68 Sample Indigenous Biotechnology Companies in Taiwan, 2018/19	123/124
Figure 355.4.69 Sample Seedling Producing Companies in Taiwan, 2018/19	125
Figure 355.4.70 Leading Recent Biotechnology Company IPOs in Taiwan	126
Figure 355.4.71 Taiwan Biotechnology Scenario, 2018/19	127
Figure 355.4.72 Business & Commercial Development in Taiwan, 2016/19	129
Figure 355.4.72 Taiwan Country Panel, 2019/20	130
Figure 355.4.73 Life Science Infrastructure History in Hong Kong	132
Figure 355.4.74 Life Science Funding Sources in Hong Kong, 2019	141
Figure 355.4.75 Life Science Research in Universities in Hong Kong, 2019	142
Figure 355.4.76 Hong Kong Biotechnology Research Funding, 2019	145
Figure 355.4.77 Hong Kong UST Knowledge Transfer Report Summary, 2016	145
Figure 355.4.78 Hong Kong Diagnostic Product Market Sources, 2019	147
Figure 355.4.79 Commercial Collaborations of Hong Kong BRI	149
Figure 355.4.80 Biotechnology Company Activities in Hong Kong, 2019	151



Figure 355.4.81 Application Areas Funding for Hong Kong Life Science Industry, 2019	152
Figure 355.4.81A Life Science Suppliers in Hong Kong, 2019	153
Figure 355.4.82 Group 1 Country Life Sciences Funding Sources, 2019	155
Figure 355.4.83 Biotechnology Business Segments & Funding by P/Rim Country, 2019	157
Figure 355.4.84 Life Sciences Research Product Funding for Group 1 Countries, 2019	158
Figure 355.4.85 Life Science Research & Product Funding Shares – Group 1 Countries, 2019	159
Figure 355.4.86 Life Science Research Product Markets – Group 1 Countries, 2019 & 2026	160
Figure 355.4.87 Australia Product Group & Reagent Product Class Sales, 2019 & 2026	162
Figure 355.4.88 South Korea Product Group & Reagent Product Class, 2019 & 2026	163
Figure 355.4.89 Singapore Product Group & Reagent Product Class, 2019 & 2026	164
Figure 355.4.90 Taiwan Product Group & Reagent Product Class, 2019 & 2026	165
Figure 355.4.90 Hong Kong Product Sales & Reagent Product Group Sales, 2019 & 2026	166
Figure 355.4.91 Asia Listed Biotechnology Companies by Country 2016	167
5. Group 2 Country Business & Life Sciences Environment: Malaysia, New Zealand, Thailand & Vietnam	168
Figure 355.4.92 Bioscience Research Structure for Malaysia	171
Figure 355.4.93 Funding Sources & Assignments for Research Funding, Malaysia, 2019	175
Figure 355.4.94 National Biotechnology Plan, Malaysia	177
Figure 355.4.96 Application Areas for Malaysian Bioeconomy, 2019	183
Figure 355.4.97 Biotechnology Company Applications, Malaysia 2019	183
Figure 355.4.98 Malaysian Funding Sources for Biotechnology Examples, Pre-NISS	184
Figure 355.4.99 Malaysia Promoted Clusters under BioNexus 3.0 Framework	185/186
Figure 355.4.100 Malaysian Biotechnology – Government Activities & Companies	187
Figure 355.4.101 Focus Area Activities in Malaysia, 2019	188
Figure 355.4.102 Application Area Developments in Malaysia, 2018/19	189
Figure 355.4.103 Life Science Research in Universities in Malaysia, 2019	190
Figure 355.4.105 Life Science Foreign Research Companies in Malaysia, 2019	192
Figure 355.4.106 Commercial Listed Biotech Companies in Malaysia, 2019	193
Figure 355.4.107 Business & Commercial Activities Malaysia	194
Figure 355.4.108 New Zealand Science & Technology Research Structure & Funding	199



Figure 355.4.109 New Zealand Company Developments, from 2005 – 2014 Strategy	201
Figure 355.4.110 New Zealand Research Investment Strategy, 2019	203
Figure 355.4.111 Funding Sources & Assignments Research Funding: N. Zealand, 2019	204
Figure 355.4.112 New Zealand Biotechnology Industry Applications, 2019	206
Figure 355.4.113 Life Science Research in Universities in New Zealand, 2019	211
Figure 355.4.114 New Zealand Biotechnology Research & Commercialisation	212
Figure 355.4.115 Activity Developments in New Zealand 2016- 2019	213
Figure 355.4.116 New Zealand Country Panel, 2019/20	214
Figure 355.4.117 Life Science Research Policy Management for Thailand	218
Figure 355.4.118 Thailand Academic Training Figures, 2013	219
Figure 355.4.119 Thailand Government Science & Technology Budget, 2019	219
Figure 355.4.120 Thailand Science Park Regional Hubs, 2019	220
Figure 355.4.121 Thailand Biotechnology Application Areas & Technologies, 2014/2021	223
Figure 355.4.122 Thailand Government Funding Sources for Biotechnology, 2019	225
Figure 355.4.123 Application Areas for Thailand Private Companies, 2019	226
Figure 355.4.124 Science Parks & Incubators in Thailand, 2019	226
Figure 355.4.125 Biotechnology Research Centres in Thailand	227
Figure 355.4.126 Some Typical Thailand Private Companies, 2019	228
Figure 355.4.127 Thailand Sector Selection Criteria 2012-2021	230
Figure 355.4.128 Biotechnology Structural Developments in Thailand, 21st Century	231
Figure 355.4.129 Biotechnology Focus Areas & Activities in Thailand, 21st Century	231
Figure 355.4.130 Biotechnology Focus & Activity Developments in Thailand – 1	232
Figure 355.4.131 Biotechnology Focus & Activity Developments in Thailand – 2	232
Figure 355.4.132 Biotechnology Focus & Activity Developments in Thailand – 3	233
Figure 355.4.133 Life Science Research Programmes in Thailand, 2014 – 2021	234/235
Figure 355.4.134 Funding Sources & Assignments for Research: Thailand, 2019	235
Figure 355.4.135 Thailand Activity Developments	236
Figure 355.4.136 Science & Technology Organisation in Vietnam	241



Figure 355.4.137 Life Science Research Programmes in Universities in Vietnam	<u>249</u>
Figure 355.4.138 Life Science Research Programmes in Vietnam Research Institutes	<u>250</u>
Figure 355.4.139 Funding Sources & Assignments for Research Funding: Vietnam, 2019	<u>252</u>
Figure 355.4.140 Activity Developments in Vietnam	<u>252</u>
Figure 355.4.141 Life Sciences Funding Sources for Group 2 Countries, 2019	<u>253</u>
Figure 355.4.142 Biotechnology Business Segments & Funding for Group 2 Countries, 2019	<u>254</u>
Figure 355.4.143 Segment Allocation of Biotechnology Funding for Group 2 Countries, 2019	<u>254</u>
Figure 355.4.144 Life Science Application Shares for All 4 Group 2 Countries, 2019	<u>255</u>
Figure 355.4.145 Life Science Research & Product Funding Shares Group 2 Countries, 2019	<u>256</u>
Figure 355.4.146 Biotechnology Research Product Funding for Group 2 Countries, 2019	<u>257</u>
Figure 355.4.147 BioResearch Reagent Product Group Shares in Group 2 Countries, 2019	<u>258</u>
Figure 355.4.148 Biotechnology Research Reagent Product Shares in Pacific Rim, 2026	<u>258</u>
Figure 355.4.149 BioResearch Product Group Sales by Country, 2019	<u>259</u>
Figure 355.4.150 BioResearch Product Group Sales by Country, 2026	<u>259</u>
Figure 355.4.151 Group 2 Total BioResearch Product Group Sales, 2019 & 2026	<u>260</u>
Figure 355.4.152 BioResearch Reagent Product Class Sales by Country, 2019	<u>261</u>
Figure 355.4.153 BioResearch Reagent Product Class Sales by Country, 2026	<u>261</u>
Figure 355.4.154 Group 2 Total BioResearch Reagent Product Class Sales, 2019 & 2026	<u>262</u>

6. Group 3 Country Business & Life Sciences Environment: Indonesia, Philippines, Myanmar & Brunei 263

Figure 355.4.155 Science & Technology Organisation in Indonesia	<u>267</u>
Figure 355.4.156 Life Science Facilities & Research Programmes in Indonesia	<u>270</u>
Figure 355.4.157 Indonesian BIORIN Project & Fields, 2004/5	<u>272</u>
Figure 355.4.158 Life Science Research Resources in Indonesia, 2012/13	<u>272</u>
Figure 355.4.159 Some Indonesian Biotechnology Companies, 2019	<u>274</u>



Figure 355.4.160 Business Developments for Indonesia in 2016-2020	<u>275</u>
Figure 355.4.161 Funding Sources & Assignments of Research Funding: Indonesia, 2019	<u>276</u>
Figure 355.4.162 Events & Regulations for Organisation of Life Sciences in Philippines	<u>280</u>
Figure 355.4.163 Life Science & Biotechnology Programmes in Philippines, 1980 to 2012	<u>286</u>
Figure 355.4.164 Life Science Research Tools in The Philippines	<u>287</u>
Figure 355.4.165 Life Science Research Programmes in The Philippines, 2010 – 2019	<u>288</u>
Figure 355.4.166 The Philippines Biotechnology Focus Areas, 2015-20	<u>289</u>
Figure 355.4.167 Typical Philippino Companies, 2019	<u>290</u>
Figure 355.4.168 Philippines Biotechnology Competitive Position Analysis	<u>291</u>
Figure 355.4.169 Philippines Biotechnology Developments	<u>292</u>
Figure 355.4.170 Philippines Country Panel	<u>293</u>
Figure 355.4.171 Funding Sources & Assignments for Research Funding: Indonesia, 2019	<u>293</u>
Figure 355.4.172 Organisation of Biotechnology in Brunei	<u>302</u>
Figure 355.4.173 Life Science & Biotechnology Programmes in Brunei	<u>303</u>
Figure 355.4.174 Group 3 Country Life Sciences Funding Sources, 2019	<u>306</u>
Figure 355.4.175 Biotechnology Business Segments & Funding for Group 3 Countries, 2019	<u>307</u>
Figure 355.4.176 Segment Allocation of Biotechnology Funding for Group 3 Countries, 2019	<u>307</u>
Figure 355.4.177 Life Science Application Shares for All 4 Group 3 Countries, 2019	<u>308</u>
Figure 355.4.178 Life Science Research & Product Funding Shares Group 3 Countries, 2019	<u>309</u>
Figure 355.4.179 Biotechnology Research Product Funding for Group 3 Countries, 2019	<u>310</u>
Figure 355.4.180. Indonesia & Philippine BioResearch Product Group Sales, 2019 & 2026	<u>311</u>
Figure 355.4.181 Group 3 Total BioResearch Product Group Sales, 2019 & 2026	<u>311</u>
Figure 355.4.182 BioResearch Reagent Product Class Shares Group 3 Countries, 2019	<u>312</u>
Figure 355.4.183 Group 3 Total BioResearch Reagent Product Class Sales, 2019 & 2026	<u>312</u>
Figure 355.4.184 Group 3 BioResearch Reagent Product Class Sales by Country, 2019	<u>313</u>
Figure 355.4.184 Group 3 BioResearch Reagent Product Class Sales by Country, 2026	<u>313</u>
Figure 355.4.186 Asia Pacific Group Emerging Country Profiles– in \$US, 2019	<u>314</u>



Adams Business Associates.

Tel: 44-(0)1494-465244

Email: aba@a-b-a.co.uk

Figure 355.4.187 Laos National Biodiversity Strategy and Action Plan, 2016-2025 _____ 321

7. Asia Pacific & Australasia Life Science Research Business Market Comparisons, 2019 & 2026 _____ 325

Figure 355.4.188 Global Venture and IPOs for Biotechnology, 2017- 2019 _____ 326

Figure 355.4.189 Life Science Segments by Asia Pacific Groups, 2019 _____ 327

Figure 355.4.190 Life Science Funding Sources for Asia Pacific Groups, 2019 _____ 328

Figure 355.4.191 Life Science Funding Segment Distribution for
Asia Pacific Groups, 2019 _____ 328

Figure 355.4.192 Life Science Applications & Research Funding for
Asia Pacific Groups, 2019 _____ 329

Figure 355.4.193 Life Science Applications & Research Funding for
Asia Pacific Groups, 2019 _____ 330

Figure 355.4.194 BioResearch Product Groups for Asia Pacific Groups, 2019 _____ 331

Figure 355.4.195 BioResearch Product Groups for Asia Pacific Groups, 2026 _____ 332

Figure 355.4.196 BioResearch Reagent Product Groups for
Asia Pacific Groups, 2019 & 2026 _____ 333

Figure 355.4.197 Life Science Suppliers in Hong Kong, 2019 _____ 334

Figure 355.4.198 Other Group 1 Country Companies Supporting
Overseas Suppliers, 2019 _____ 335

Figure 355.4.199 Group 2 Country Companies Supporting Overseas Suppliers, 2019 _____ 336

Figure 355.4.200 Group 3 Country Companies Supporting Overseas Suppliers, 2019 _____ 337

Figure 355.4.A1 2019 Currency Exchange Rates & GDP Growth for Pacific Rim Countries _____ 338

Figure 355.4.A2.1 Life Science Research Reagent Classification: BioResearch Reagents _____ 340

Figure 355.4.A2.2 Life Science Research Product Listings, 2019 _____ 342